Analysts await Inogen, Inc (NASDAQ:INGN) to report earnings on Mar, 14 for the fiscal quarter ending Dec 2015.

They expect $0.07 EPS, up 14.29% or $0.01 from last year’s $0.06 per share.

At the moment 5 analysts are watching Inogen, Inc (NASDAQ:INGN), 4 rate it “Buy”, 1 “Outperform”, 0 “Underperform”, 0 “Sell”, while 0 “Hold”.

Looking forward, for the quarter ending Mar-16, 4 analysts have a mean sales target of 40.43 million. For the quarter ending Jun-16, 4 analysts have a mean sales target of 51.51 million whilst for the year ending Dec-16, 5 analysts have a mean target of 181.32 million.

In terms of earnings per share, 3 analysts have a 0.11 EPS mean target for the quarter ending Mar-16, for the quarter ending Jun-16, 3 analysts have a 0.18 EPS mean target and for the quarter ending Jun-16 there are 4 estimates of 0.54 EPS.

The biggest institutional shareholders in Inogen, Inc include Novo A/S which owns 4 million shares in the company valued at $142.29 million. Versant Ventures II LLC is the second biggest holder with 2 million shares currently valued at 53.30 million whilst BlackRock Advisors LLC has 1 million shares valued at 59.10 million.

Total shares held by institutions as of the most recent company filings are 23,021,944 with a reported 2,330,111 bought and 1,094,532 sold. These holdings make up 97.4% of the company’s outstanding shares.

Currently insiders hold 203,432 shares in the business which makes up 1.04% of shares. The biggest holder currently is Ms. Alison Bauerlein who owns 53,890 shares (0.27% of those outstanding), whilst Mr. Byron Myers holds 48,185 (0.25% of shares outstanding) and Mr. Brenton Taylor holds 43,351 (0.22% of shares outstanding).

The stock increased 3.75% or $1.24 during the last trading session.